Holen Sie sich die Stockscreener-App
7.28
4.15%
0.29
Handel nachbörslich:
7.03
-0.25
-3.43%
Schlusskurs vom Vortag:
$6.99
Offen:
$6.95
24-Stunden-Volumen:
1.07M
Relative Volume:
0.86
Marktkapitalisierung:
$395.14M
Einnahmen:
$1.02B
Nettoeinkommen (Verlust:
$-757.20M
KGV:
-0.4932
EPS:
-14.76
Netto-Cashflow:
$-257.90M
1W Leistung:
-0.68%
1M Leistung:
+17.04%
6M Leistung:
-26.32%
1J Leistung:
-39.43%
1-Tages-Spanne:
$6.95
$7.31
1-Wochen-Bereich:
$6.74
$7.65
52-Wochen-Spanne:
$4.02
$15.10
Emergent Biosolutions Inc Stock (EBS) Company Profile
Firmenname
Emergent Biosolutions Inc
Sektor
Telefon
240-631-3200
Adresse
300 PROFESSIONAL DR, GAITHERSBURG, MD
Vergleichen Sie EBS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
7.28 | 397.86M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
150.03 | 70.70B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.74 | 46.87B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.59 | 45.41B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.31 | 18.96B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
297.33 | 13.54B | 2.99B | 1.21B | 1.13B | 25.06 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-22 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-03-07 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Underweight |
| 2023-08-29 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2023-04-10 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-11-10 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-04-29 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-11-08 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2021-05-05 | Herabstufung | Argus | Buy → Hold |
| 2021-04-07 | Eingeleitet | The Benchmark Company | Buy |
| 2021-02-24 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | Fortgesetzt | JP Morgan | Neutral |
| 2020-07-31 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-09-04 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | Hochstufung | Goldman | Neutral → Buy |
| 2018-08-03 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-06-13 | Eingeleitet | Argus | Buy |
| 2018-04-25 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | Eingeleitet | Goldman | Neutral |
| 2018-01-16 | Bestätigt | Chardan Capital Markets | Buy |
| 2016-06-28 | Bestätigt | Singular Research | Buy |
| 2016-04-15 | Eingeleitet | Chardan Capital Markets | Buy |
| 2016-03-28 | Eingeleitet | Singular Research | Buy |
| 2016-02-19 | Eingeleitet | Wells Fargo | Outperform |
| 2014-05-15 | Eingeleitet | Summer Street Research | Buy |
| 2011-05-31 | Bestätigt | WBB Securities | Strong Buy |
| 2011-01-10 | Bestätigt | Wedbush | Outperform |
| 2010-11-05 | Bestätigt | Wedbush | Outperform |
| 2010-08-18 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | Bestätigt | Caris & Company | Buy |
Alle ansehen
Emergent Biosolutions Inc Aktie (EBS) Neueste Nachrichten
Emergent Signs $174M Manufacturing Deal For AstraZeneca’s Covid-19 Candidate - TipRanks
What makes Emergent BioSolutions Inc. stock price move sharplyPotential Rocket List - beatles.ru
Lobbying Update: $440,000 of EMERGENT BIOSOLUTIONS INC lobbying was just disclosed - Nasdaq
Emergent BioSolutions to Report Second Quarter 2025 Financial Re - GuruFocus
Emergent BioSolutions Inc. to Host Q2 2025 Financial Results Conference Call on August 6 - Nasdaq
Emergent BioSolutions Q2 2025 Earnings Call Scheduled for August 6: Key Details Inside - Stock Titan
Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025 - TradingView
Government Contract Update: $52M payment to EMERGENT BIOSOLUTIONS CANADA INC - Nasdaq
Emergent BioSolutions signs contract modification award for CNJ-016 - MSN
Benchmark Co. Maintains Emergent BioSolutions(EBS.US) With Buy Rating, Maintains Target Price $12 - 富途牛牛
Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts - The Manila Times
Emergent BioSolutions Stock Rises After New US Order For Smallpox Complication Therapy - Stocktwits
Emergent BioSolutions secures contract modification for smallpox treatment By Investing.com - Investing.com South Africa
Emergent BioSolutions secures contract modification for smallpox treatment - Investing.com Australia
Emergent BioSolutions (EBS) Expands Smallpox Vaccine Contract wi - GuruFocus
Emergent BioSolutions (EBS) Secures Smallpox Preparedness Contra - GuruFocus
Emergent BioSolutions Gets $51.9 Million Contract Modification for Smallpox Preparedness - MarketScreener
Emergent BioSolutions stock rises on government contract modification By Investing.com - Investing.com Canada
Emergent BioSolutions stock rises on government contract modification - Investing.com
Emergent BioSolutions Secures Contract Modification for Additional VIGIV Doses to Support U.S. Smallpox Preparedness - Quiver Quantitative
Emergent BioSolutions Strengthens US Biodefense Arsenal with $51.9M Government Contract - Stock Titan
Emergent BioSolutions Secures $51.9 Million Contract Modificatio - GuruFocus
Lobbying Update: $40,000 of EMERGENT BIOSOLUTIONS lobbying was just disclosed - Quiver Quantitative
Is Emergent BioSolutions (NYSE:EBS) Using Debt In A Risky Way? - simplywall.st
Emergent BioSolutions adds KLOXXADO to online naloxone platform By Investing.com - Investing.com India
Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® ( - GuruFocus
Investors Can Still File Late Claims in Emergent BioSolutions Settlement - TradingView
Emergent BioSolutions Inc.(NYSE: EBS) added to Russell 2500 Value Index - MarketScreener
Is Emergent BioSolutions, Inc. overvalued or undervalued? - MarketsMojo
Emergent BioSolutions secures $62.4 million contract for botulism antitoxin By Investing.com - Investing.com South Africa
Emergent BioSolutions Announces Addition to Russell 3000® Index - The Manila Times
Emergent BioSolutions to join Russell 3000 Index after market close June 27 - Investing.com
EBS Stock Up 1.4% after 1-Day Win Streak - Trefis
Abuse Deterrent Formulations Market Exploding While Estimated to Reach $39 Million In 2025 and $54 Million By 2030 - GlobeNewswire
Government Contract Update: $62M payment to EMERGENT BIOSOLUTIONS CANADA INC - Nasdaq
BRIEF—LigaChem links up with NovaRock - The Pharma Letter
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Emergent BioSolutions (EBS) Investors with $100k+ Losses to Contact Its Attorneys Now, Securities Fraud Case Pending, Firm Investigating CEO’s Insider Sales - ACCESS Newswire
Emergent BioSolutions at Jefferies Conference: Strategic Transformation By Investing.com - Investing.com Canada
Squarepoint Ops LLC Has $451,000 Stake in Emergent BioSolutions Inc. (NYSE:EBS) - Defense World
Emergent BioSolutions (EBS) Partners with Foundation for Opioid Awareness | EBS Stock News - GuruFocus
Emergent BioSolutions Supports Victoria's Voice Foundation's Nat - GuruFocus
Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies | EBS Stock News - GuruFocus
Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies - The Manila Times
Breaking: Dramatic 34% Drop in US Opioid Deaths as Emergent Expands Life-Saving Naloxone Access - Stock Titan
Vaccine Contract Manufacturing Market Set to Witness - openPR.com
Biodefense Market Set to Witness Significant GrowthEmergent BioSolutions Inc., SIGA Technologies - openPR.com
Bank of America Corp DE Boosts Stake in Emergent BioSolutions Inc. (NYSE:EBS) - Defense World
Northern Trust Corp Acquires 3,692 Shares of Emergent BioSolutions Inc. (NYSE:EBS) - Defense World
Emergent BioSolutions discloses CEO stock purchase - MSN
Emergent Biosolutions Settlement Receives Preliminary Approval - TipRanks
Emergent BioSolutions at RBC Conference: Strategic Turnaround Focus By Investing.com - Investing.com India
Finanzdaten der Emergent Biosolutions Inc-Aktie (EBS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.09%
3.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):